No Data
No Data
Zhejiang Jolly Pharmaceutical (300181.SZ) has cumulatively repurchased 1.24% of the shares, with a total investment of 0.127 billion yuan.
Zhejiang Jolly Pharmaceutical (300181.SZ) announced that as of August 31, 2024, the company will trade through centralized bidding...
Could The Market Be Wrong About Zhejiang Jolly Pharmaceutical Co.,LTD (SZSE:300181) Given Its Attractive Financial Prospects?
Zhejiang Jolly Pharmaceutical: The regions that won the centralized procurement bids have basically achieved volume-based pricing and will develop 10 varieties of Wuling series.
①The company has seen both gains and losses in centralized procurement, for example, sales in centralized procurement areas have increased significantly compared to non-centralized procurement areas, but the company once lost the bid in the procurement of Bacillus Subtilis; ②Due to the reduction of sales expenses and other reasons, the net income of the company in the areas where it won the bid in centralized procurement has actually increased; ③Currently, the company's production capacity utilization rate of Trametes versicolor powder is relatively high and expansion projects for the second phase are underway, with future considerations for planning new production capacity.
Zhejiang Jolly Pharmaceutical (300181.SZ): Bailin capsule has completed the online listing in 28 provinces and has not been officially sold yet.
On August 16, Gelunhui reported that Zhejiang Jolly Pharmaceutical (stock code: 300181.SZ) has completed the network listing of Bailing Capsules in 28 provinces and has not yet been officially launched for sale.
Zhejiang Jolly Pharmaceutical (300181.SZ) has repurchased 0.4328 million shares for a total of 6.3996 million yuan.
On August 13th, Gelonhui announced that Zhejiang Jolly Pharmaceutical (300181.SZ) had implemented its first buyback through the stock repurchase dedicated securities account via centralized bidding trading. The number of shares repurchased by the company this time was 432,800 shares, accounting for 0.06% of the company's current total share capital. The highest fill price was 14.95 yuan/share, the lowest fill price was 14.70 yuan/share, and the total transaction amount was RMB 6,399,641 (excluding transaction fees). This buyback complies with the company's share repurchase plan and relevant laws and regulations.
Zhejiang Jolly Pharmaceutical (300181.SZ): Sales of out-of-hospital end mainly include sales of OTC end and internet plus-related end, accounting for a little over 10% of sales.
Zhejiang Jolly Pharmaceutical (300181.SZ) recently conducted investor relations activities regarding the growth of the outpatient terminal in the first half of this year. The company's outpatient terminal mainly includes OTC and internet-related sales, accounting for more than 10% of total sales. In the first half of this year, due to the relatively small overall base of OTC products, the growth rate was slightly faster than that of the inpatient terminal. The company attaches great importance to the sales of OTC products. Its focus in the future is to improve the acceptance of the outpatient terminal and enhance consumers' health education, with the aim of increasing the sales ratio of the outpatient terminal to at least 20%. Meanwhile, the company has also laid out its plan.
No Data